A prostate cancer patient with Gleason (4+3), PSA 18, spread to seminal vesicles but not to lymph nodes. I am...

Understanding NRG-GU013 for Your Prostate Cancer

Thank you for sharing your clinical situation. Based on your Gleason 4+3, PSA 18, and seminal vesicle involvement without lymph node spread, you have locally advanced prostate cancer — this is an important distinction because it affects which trials and treatments are appropriate for you.

What I Can Tell You About Clinical Trials Generally

According to the NCCN Guidelines for Prostate Cancer, clinical trials are an important option to consider, especially for locally advanced disease. The guidelines emphasize that "all of the standard of care therapy also came from being in clinical trials. Anything that's leading edge right now will be from clinical trials."

However, I don't have specific details about NRG-GU013's protocol, eligibility criteria, or current data in my available resources. This is important because:

• Trial details change as enrollment progresses
• Your specific eligibility depends on factors beyond staging (age, comorbidities, prior treatments, performance status)
• The trial's current phase and preliminary data affect risk/benefit

General Framework: Questions to Ask About ANY Clinical Trial

When evaluating NRG-GU013 specifically, ask your oncologist:

About the Trial Design:

1. What is the trial phase (1, 2, or 3)? Phase 1 focuses on safety; Phase 3 compares to standard treatment.
2. What is the primary endpoint (what outcome is being measured)?
3. How does the experimental arm compare to standard of care for locally advanced prostate cancer?

About Your Fit: 4. Am I eligible given my Gleason score, PSA, and seminal vesicle involvement? 5. What are the inclusion/exclusion criteria, and do I meet all of them?

About Logistics & Safety: 6. What is the treatment schedule and time commitment? 7. What are the known side effects, and how do they compare to standard treatment? 8. What monitoring will occur, and how often?

About Your Options: 9. What is the standard of care treatment I'd be comparing this to? 10. If the trial doesn't work for me, what are my next options?

Standard of Care Context for Your Stage

According to NCCN Guidelines for Early-Stage Prostate Cancer, locally advanced disease (seminal vesicle involvement) typically involves:

• Radiation therapy (often combined with hormone therapy/ADT)
• Radical prostatectomy (surgical removal of the prostate) in selected cases
• Hormone therapy (ADT) — androgen deprivation therapy that blocks testosterone

The guidelines note that treatment intensification — combining multiple approaches — is increasingly standard for higher-risk disease like yours.

Key Considerations for Your Decision

Potential Advantages of Clinical Trials:

• Access to newer treatment approaches not yet widely available
• Close monitoring and supportive care
• Contributing to medical knowledge that helps future patients
• Potential benefit if the experimental approach is effective

Potential Considerations:

• Unknown efficacy compared to proven standard treatments
• Possible additional side effects from experimental therapy
• More frequent clinic visits and testing
• Risk that the experimental arm may not be superior to standard care

Your Next Steps

1. Request the trial protocol — Ask the trial coordinator for the full protocol document so you can review the experimental treatment details
2. Get a second opinion — Consider discussing NRG-GU013 with another oncologist familiar with prostate cancer trials
3. Research the trial — Visit ClinicalTrials.gov and search "NRG-GU013" for the official trial summary, eligibility criteria, and contact information
4. Ask about alternatives — Ensure you understand what standard treatments are available to you if you don't enroll

Important Resources

According to the NCCN Guidelines, patients should ask their care team about:

• Germline (inherited) and tumor genetic testing, which may identify additional treatment options
• Whether molecular biomarker testing has been done on your tumor
• Clinical trial matching services that can identify trials suited to your specific case

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.